-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The field of biomedicine has become one of the industries that have attracted a lot of attention in the capital market and are regarded as very promising
.
Affected by the quadruple resonance of policies, capital, enterprises and talents, the market scale of the domestic biopharmaceutical industry continues to expand
.
According to data from the National Bureau of Statistics, as of 2020, the market size of China's biopharmaceutical industry is 3.
57 trillion yuan, an increase of 8.
51% over 2019
.
It is estimated that by 2022, the market size will exceed 4 trillion yuan
.
Innovative drugs are undoubtedly the main driving force for the further expansion of China's biopharmaceutical market
.
According to statistics, in 2021, the State Food and Drug Administration will approve a total of 76 new drugs (excluding new indications and vaccines), involving popular products such as anti-PD-L1 monoclonal antibodies, CAR-T cell therapy products, and antibody-conjugated (ADC) drugs.
, far exceeding the 48 in 2020, setting a new high in number, which can be described as a fruitful year
.
Entering 2022, with the continued increase in favorable policies and the continuous improvement of the innovation capabilities of domestic pharmaceutical companies, the pace of new drug R&D and listing will continue to accelerate, and pharmaceutical companies will also accelerate their entry into the "harvest period"
.
It is reported that at the beginning of 2022, there will be news of a batch of new drugs being approved for marketing
.
On January 3, Hengrui Medicine announced that the State Food and Drug Administration recently approved the company's two Class 1 innovative drugs for listing, namely: combined with fulvestrant for hormone receptor (HR) positive, human epidermal growth Dalcilide Isethionate for the treatment of factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer that has progressed after endocrine therapy, and Proline Henger for improving glycemic control in adults with type 2 diabetes List the net tablets
.
Among them, Dalcil is the first China-originated CDK4/6 inhibitor, and Henggliflozin is the first domestically-made innovative SGLT2 inhibitor that has been approved.
So far, Hengrui Medicine has 10 innovative drugs on the market.
.
According to Insight database screening, 20 blockbuster new drugs are expected to be approved for marketing in 2022, including 2 third-generation EGFR-TKIs, 2 PI3K inhibitors, 2 ALK inhibitors, 2 CDK4/6 inhibitors, 2 ADC products, etc.
, involving multinational pharmaceutical companies such as Takeda, Eli Lilly, and Pfizer, as well as local pharmaceutical companies such as Hansoh, Betta, and CSPC
.
At the same time, the number and speed of new drugs entering health insurance is changing
.
Not long ago, the results of the national pharmaceutical negotiation in 2021 were released.
A total of 94 drugs (including 67 outside the catalog and 27 within the catalog) were successfully negotiated, with an overall success rate of 80.
34%
.
Among them, a total of 20 new drugs participated in the National Medical Insurance Talk for the first time, including PARP inhibitors, BTK inhibitors, ALK inhibitors, ADC drugs, CAR-T therapy,
etc.
The industry pointed out that judging from the adjustment of the medical insurance catalogue in recent years, the proportion of innovative drugs included in medical insurance is increasing year by year
.
The time from the launch of new drugs to the inclusion of medical insurance has also been significantly shortened.
Statistics show that from 2016 to 2020, a total of 34 innovative drugs were launched, of which 26 were successfully included in the medical insurance catalogue, accounting for nearly 80%
.
For new drugs successfully included in the medical insurance list, it is expected to accelerate the commercialization process, increase market share, and achieve product volume
.
In addition, the broad market prospects of the biopharmaceutical industry also attract a large amount of capital to enter
.
Statistics show that in 2021, there will be 53 IPOs of A-share pharmaceutical companies, raising more than 80 billion yuan
.
Among them, in the first half of 2021 alone, the total domestic medical and health financing amounted to 92.
7 billion yuan (only angels’ turn to pre-IPO financing), a year-on-year increase of 70%, a record high for the same period
.
At the same time, the number of financing events reached 546
.
Entering 2022, it is expected that the ability of pharmaceutical companies to absorb gold will also strengthen
.
It is reported that on the first day of the opening of the A-share New Year, 18 billion yuan of funds have poured into the A-share pharmaceutical sector
.
.
Affected by the quadruple resonance of policies, capital, enterprises and talents, the market scale of the domestic biopharmaceutical industry continues to expand
.
According to data from the National Bureau of Statistics, as of 2020, the market size of China's biopharmaceutical industry is 3.
57 trillion yuan, an increase of 8.
51% over 2019
.
It is estimated that by 2022, the market size will exceed 4 trillion yuan
.
Innovative drugs are undoubtedly the main driving force for the further expansion of China's biopharmaceutical market
.
According to statistics, in 2021, the State Food and Drug Administration will approve a total of 76 new drugs (excluding new indications and vaccines), involving popular products such as anti-PD-L1 monoclonal antibodies, CAR-T cell therapy products, and antibody-conjugated (ADC) drugs.
, far exceeding the 48 in 2020, setting a new high in number, which can be described as a fruitful year
.
Entering 2022, with the continued increase in favorable policies and the continuous improvement of the innovation capabilities of domestic pharmaceutical companies, the pace of new drug R&D and listing will continue to accelerate, and pharmaceutical companies will also accelerate their entry into the "harvest period"
.
It is reported that at the beginning of 2022, there will be news of a batch of new drugs being approved for marketing
.
On January 3, Hengrui Medicine announced that the State Food and Drug Administration recently approved the company's two Class 1 innovative drugs for listing, namely: combined with fulvestrant for hormone receptor (HR) positive, human epidermal growth Dalcilide Isethionate for the treatment of factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer that has progressed after endocrine therapy, and Proline Henger for improving glycemic control in adults with type 2 diabetes List the net tablets
.
Among them, Dalcil is the first China-originated CDK4/6 inhibitor, and Henggliflozin is the first domestically-made innovative SGLT2 inhibitor that has been approved.
So far, Hengrui Medicine has 10 innovative drugs on the market.
.
According to Insight database screening, 20 blockbuster new drugs are expected to be approved for marketing in 2022, including 2 third-generation EGFR-TKIs, 2 PI3K inhibitors, 2 ALK inhibitors, 2 CDK4/6 inhibitors, 2 ADC products, etc.
, involving multinational pharmaceutical companies such as Takeda, Eli Lilly, and Pfizer, as well as local pharmaceutical companies such as Hansoh, Betta, and CSPC
.
At the same time, the number and speed of new drugs entering health insurance is changing
.
Not long ago, the results of the national pharmaceutical negotiation in 2021 were released.
A total of 94 drugs (including 67 outside the catalog and 27 within the catalog) were successfully negotiated, with an overall success rate of 80.
34%
.
Among them, a total of 20 new drugs participated in the National Medical Insurance Talk for the first time, including PARP inhibitors, BTK inhibitors, ALK inhibitors, ADC drugs, CAR-T therapy,
etc.
The industry pointed out that judging from the adjustment of the medical insurance catalogue in recent years, the proportion of innovative drugs included in medical insurance is increasing year by year
.
The time from the launch of new drugs to the inclusion of medical insurance has also been significantly shortened.
Statistics show that from 2016 to 2020, a total of 34 innovative drugs were launched, of which 26 were successfully included in the medical insurance catalogue, accounting for nearly 80%
.
For new drugs successfully included in the medical insurance list, it is expected to accelerate the commercialization process, increase market share, and achieve product volume
.
In addition, the broad market prospects of the biopharmaceutical industry also attract a large amount of capital to enter
.
Statistics show that in 2021, there will be 53 IPOs of A-share pharmaceutical companies, raising more than 80 billion yuan
.
Among them, in the first half of 2021 alone, the total domestic medical and health financing amounted to 92.
7 billion yuan (only angels’ turn to pre-IPO financing), a year-on-year increase of 70%, a record high for the same period
.
At the same time, the number of financing events reached 546
.
Entering 2022, it is expected that the ability of pharmaceutical companies to absorb gold will also strengthen
.
It is reported that on the first day of the opening of the A-share New Year, 18 billion yuan of funds have poured into the A-share pharmaceutical sector
.
